166 related articles for article (PubMed ID: 37528288)
1. Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer.
Rebhan K; Stelzer PD; Pradere B; Rajwa P; Kramer G; Hofmann B; Resch I; Yurdakul O; Laccone FA; Bujalkova MG; Smogavec M; Tan YY; Ristl R; Shariat SF; Egger G; Hassler MR
World J Urol; 2023 Aug; 41(8):2091-2097. PubMed ID: 37528288
[TBL] [Abstract][Full Text] [Related]
2. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.
Berchuck JE; Boiarsky D; Silver R; Sunkara R; McClure HM; Tsai HK; Siegmund S; Tewari AK; Nowak JA; Lindeman NI; Rana HQ; Choudhury AD; Pomerantz MM; Freedman ML; Van Allen EM; Taplin ME
JCO Precis Oncol; 2022 Aug; 6():e2200329. PubMed ID: 36103646
[TBL] [Abstract][Full Text] [Related]
3. Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study.
Nacer DF; Vallon-Christersson J; Nordborg N; Ehrencrona H; Kvist A; Borg Å; Staaf J
Genome Med; 2023 Apr; 15(1):25. PubMed ID: 37060015
[TBL] [Abstract][Full Text] [Related]
4. Rate of Pathogenic Germline Variants in Patients With Lung Cancer.
Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED
JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258
[TBL] [Abstract][Full Text] [Related]
5. Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.
Sabol RA; Ledet EM; Jaeger E; Hatton W; Moses M; Lankford A; Zaheria A; Barata P; Layton JL; Lewis BE; Sartor O
Prostate; 2021 May; 81(7):427-432. PubMed ID: 33760238
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers.
Hao S; Zhao X; Fan Y; Liu Z; Zhang X; Li W; Yuan H; Zhang J; Zhang Y; Ma T; Tao H
Cancer Med; 2023 Sep; 12(17):18394-18404. PubMed ID: 37610374
[TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study.
Uson PLS; Samadder NJ; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Faigel DO; Fukami N; Pannala R; Kunze K; Golafshar M; Klint M; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T
Clin Transl Gastroenterol; 2021 Oct; 12(10):e00414. PubMed ID: 34620795
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial.
Shore N; Gazi M; Pieczonka C; Heron S; Modh R; Cahn D; Belkoff LH; Berger A; Mazzarella B; Veys J; Idom C; Morris D; Jayram G; Engelman A; Bukkapatnam R; Dato P; Bevan-Thomas R; Cornell R; Wise DR; Hardwick MK; Hernandez RD; Rojahn S; Layman P; Hatchell KE; Heald B; Nussbaum RL; Nielsen SM; Esplin ED
Eur Urol Oncol; 2023 Oct; 6(5):477-483. PubMed ID: 37574391
[TBL] [Abstract][Full Text] [Related]
9. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
Giri VN; Hegarty SE; Hyatt C; O'Leary E; Garcia J; Knudsen KE; Kelly WK; Gomella LG
Prostate; 2019 Mar; 79(4):333-339. PubMed ID: 30450585
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.
Nicolosi P; Ledet E; Yang S; Michalski S; Freschi B; O'Leary E; Esplin ED; Nussbaum RL; Sartor O
JAMA Oncol; 2019 Apr; 5(4):523-528. PubMed ID: 30730552
[TBL] [Abstract][Full Text] [Related]
11. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population.
Senda N; Kawaguchi-Sakita N; Kawashima M; Inagaki-Kawata Y; Yoshida K; Takada M; Kataoka M; Torii M; Nishimura T; Kawaguchi K; Suzuki E; Kataoka Y; Matsumoto Y; Yoshibayashi H; Yamagami K; Tsuyuki S; Takahara S; Yamauchi A; Shinkura N; Kato H; Moriguchi Y; Okamura R; Kan N; Suwa H; Sakata S; Mashima S; Yotsumoto F; Tachibana T; Tanaka M; Togashi K; Haga H; Yamada T; Kosugi S; Inamoto T; Sugimoto M; Ogawa S; Toi M
Cancer Sci; 2021 Aug; 112(8):3338-3348. PubMed ID: 34036661
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.
Samadder NJ; Riegert-Johnson D; Boardman L; Rhodes D; Wick M; Okuno S; Kunze KL; Golafshar M; Uson PLS; Mountjoy L; Ertz-Archambault N; Patel N; Rodriguez EA; Lizaola-Mayo B; Lehrer M; Thorpe CS; Yu NY; Esplin ED; Nussbaum RL; Sharp RR; Azevedo C; Klint M; Hager M; Macklin-Mantia S; Bryce AH; Bekaii-Saab TS; Sekulic A; Stewart AK
JAMA Oncol; 2021 Feb; 7(2):230-237. PubMed ID: 33126242
[TBL] [Abstract][Full Text] [Related]
13. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer.
Heald B; Mokhtary S; Nielsen SM; Rojahn S; Yang S; Michalski ST; Esplin ED
Gynecol Oncol; 2022 Aug; 166(2):344-350. PubMed ID: 35691755
[TBL] [Abstract][Full Text] [Related]
14. Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer.
Darst BF; Saunders E; Dadaev T; Sheng X; Wan P; Pooler L; Xia LY; Chanock S; Berndt SI; Wang Y; Patel AV; Albanes D; Weinstein SJ; Gnanapragasam V; Huff C; Couch FJ; Wolk A; Giles GG; Nguyen-Dumont T; Milne RL; Pomerantz MM; Schmidt JA; Travis RC; Key TJ; Stopsack KH; Mucci LA; Catalona WJ; Marosy B; Hetrick KN; Doheny KF; MacInnis RJ; Southey MC; Eeles RA; Wiklund F; Conti DV; Kote-Jarai Z; Haiman CA
JAMA Oncol; 2023 Nov; 9(11):1514-1524. PubMed ID: 37733366
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.
Abdel-Razeq H; Al-Azzam K; Elemian S; Abu-Fares H; Abu Sheikha A; Bani Hani H; Bater R; Sharaf B; Heald B; Esplin ED; Nielsen SM; Alkyam M; Abujamous L; Al-Attary A
Mol Genet Genomic Med; 2023 Apr; 11(4):e2125. PubMed ID: 36537080
[TBL] [Abstract][Full Text] [Related]
16. Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing.
Jalloul N; Gomy I; Stokes S; Gusev A; Johnson BE; Lindeman NI; Macconaill L; Ganesan S; Garber JE; Khiabanian H
JCO Precis Oncol; 2021; 5():. PubMed ID: 34820595
[TBL] [Abstract][Full Text] [Related]
17. Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer.
Gheybi K; Jiang J; Mutambirwa SBA; Soh PXY; Kote-Jarai Z; Jaratlerdsiri W; Eeles RA; Bornman MSR; Hayes VM
J Natl Compr Canc Netw; 2023 Mar; 21(3):289-296.e3. PubMed ID: 36898365
[TBL] [Abstract][Full Text] [Related]
18. Germline Genetic Testing in Unselected Squamous and Non-Squamous Head and Neck Cancers.
Brake DA; Idler BM; Kunze KL; Golafshar MA; Heald B; Young S; Klint M; Barrus K; Esplin ED; Nussbaum RL; Samadder NJ; Hinni ML; Chang BA
Laryngoscope; 2023 Dec; 133(12):3378-3388. PubMed ID: 37132629
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer.
Woodward ER; van Veen EM; Forde C; Harkness EF; Byers HJ; Ellingford JM; Burghel GJ; Schlech H; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ; Gareth Evans D
Genet Med; 2021 Oct; 23(10):1969-1976. PubMed ID: 34113003
[TBL] [Abstract][Full Text] [Related]
20. Germline Testing of Patients With Non-small Cell Lung Cancers Demonstrating Incidentally Uncovered BRCA2 Apparent Pathogenic Germline Variants.
Sorscher S
Clin Lung Cancer; 2022 Nov; 23(7):e405-e407. PubMed ID: 35977876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
